Seventy-one percent of healthcare executives agree that shifting home-based cancer care to their healthcare organizations as soon as possible will create "organizational success," according to a Reimagine Care survey.
Nearly 6 out of 10 healthcare executives are "extremely" or "very open" to making home-centered cancer care a reality at their healthcare organizations, according to a new Reimagine Care survey. The survey also found 60% of surveyed executives expressed concern their organizations may fall behind if they don't make the shift to home-centered cancer care in the very near future.
Patients are a significant part to changing perceptions of healthcare executives. Data found four out of five health system leaders feel that improving patient experience, satisfaction, and outcomes are top reasons for adopting home-centered oncology care models. This reflects the findings of another recent survey which found 95% of all patients interviewed preferred chemotherapy and supportive cancer treatments at home as opposed to facility-based care.
Executives recognize that home-centered oncology care is gaining traction with 66% of executives agreeing that it represents a "real opportunity for growth" for their health systems, according to the survey. Early adopters of this new home-based option can gain a significant market advantage. With that being said, 60% of executives expressed concern that their organizations may fall behind if they don't make the shift to home-centered cancer care.
Aaron Gerber, MD, co-founder and CEO of Reimagine Care stressed the survey results illustrate the urgent need to give patients a new path to receiving cancer drugs and supportive cancer care.
"The data shows healthcare executives already see home-centered cancer care as a great fit for many patients because it offers a better experience and more affordable, safer care," Gerber said. "The executives we surveyed and those we have spoken with across the country have told us that the shift to home-based cancer care is inevitable and possible – and that they see these home-centered alternatives as an opportunity to differentiate themselves from competitors while growing their share in a critical and competitive service line."
This adoption is, again, doable, but could have it's concerning challenges
Healthcare executives cited financial constraints as the most difficult barriers to overcome, with 57% of respondents ranking the development of sustainable contracting and payment models as the most significant challenge. Those who are open to home-centered cancer care, but don't yet offer any aspects of it are two times more likely to consider payments and contracting as "extremely" or "very difficult" compared to those who already offer some form of the dual care delivery model, the survey said. However, the data also reflects that healthcare executives do not necessarily perceive these challenges as barriers to adoption but rather as opportunities to innovate and learn.
Healthcare executives do see a need for expert guidance and partnership to reach that level of success they perceive in home-based cancer care.
Nearly half of those surveyed are extremely interested in finding an external partner to help address the potential challenges and speed up the critical transition to home-enabled oncology care. Thirty-one percent cited the ability to reach the right patients at the right time using predictive analytics are a critical program element that partners can help to address. Twenty-six percent of respondents also cited a strong need for support with financial sustainability models through value-based contracting.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen